JP2015509489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509489A5 JP2015509489A5 JP2014556787A JP2014556787A JP2015509489A5 JP 2015509489 A5 JP2015509489 A5 JP 2015509489A5 JP 2014556787 A JP2014556787 A JP 2014556787A JP 2014556787 A JP2014556787 A JP 2014556787A JP 2015509489 A5 JP2015509489 A5 JP 2015509489A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cell
- shmt2
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 44
- 210000004881 tumor cell Anatomy 0.000 claims 44
- 101710197776 Serine hydroxymethyltransferase 2 Proteins 0.000 claims 36
- 102100034606 Serine hydroxymethyltransferase, mitochondrial Human genes 0.000 claims 36
- 238000000034 method Methods 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 11
- 210000001519 tissue Anatomy 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 9
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 claims 6
- 108010014977 glycine cleavage system Proteins 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010061968 Gastric neoplasm Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 238000003364 immunohistochemistry Methods 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 4
- 108010058065 Aminomethyltransferase Proteins 0.000 claims 3
- 102100039338 Aminomethyltransferase, mitochondrial Human genes 0.000 claims 3
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 claims 3
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 claims 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 102100025506 Glycine cleavage system H protein, mitochondrial Human genes 0.000 claims 3
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 claims 3
- 101000856845 Homo sapiens Glycine cleavage system H protein, mitochondrial Proteins 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000012018 Yolk sac tumor Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 208000001991 endodermal sinus tumor Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 101000998096 Homo sapiens Glycine dehydrogenase (decarboxylating), mitochondrial Proteins 0.000 claims 2
- 208000000811 Mesothelial Neoplasms Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 108091030071 RNAI Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000010197 meta-analysis Methods 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 210000004882 non-tumor cell Anatomy 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 108010036684 Glycine Dehydrogenase Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101150072584 SHMT-2 gene Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229960003151 mercaptamine Drugs 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000001600 ovarian endodermal sinus tumor Diseases 0.000 claims 1
- 208000011932 ovarian sarcoma Diseases 0.000 claims 1
- 208000030342 ovarian yolk sac tumor Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597550P | 2012-02-10 | 2012-02-10 | |
| US61/597,550 | 2012-02-10 | ||
| PCT/US2013/025601 WO2013120086A1 (en) | 2012-02-10 | 2013-02-11 | Inhibition of the glycine cleavage system for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509489A JP2015509489A (ja) | 2015-03-30 |
| JP2015509489A5 true JP2015509489A5 (enExample) | 2016-04-07 |
Family
ID=48948101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556787A Pending JP2015509489A (ja) | 2012-02-10 | 2013-02-11 | がんの処置のためのグリシン開裂系の阻害 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9493775B2 (enExample) |
| EP (1) | EP2811991A4 (enExample) |
| JP (1) | JP2015509489A (enExample) |
| AU (1) | AU2013216703A1 (enExample) |
| CA (1) | CA2864161A1 (enExample) |
| IL (1) | IL234046A0 (enExample) |
| NZ (1) | NZ630026A (enExample) |
| SG (1) | SG11201404779TA (enExample) |
| WO (1) | WO2013120086A1 (enExample) |
| ZA (1) | ZA201406124B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8741591B2 (en) | 2009-10-09 | 2014-06-03 | The Research Foundation For The State University Of New York | pH-insensitive glucose indicator protein |
| WO2012064286A1 (en) * | 2010-11-11 | 2012-05-18 | Agency For Science, Technology And Research | Targeting metabolic enzymes in human cancer |
| US10287331B2 (en) | 2013-04-15 | 2019-05-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Mitochondrial proteins constructs and uses thereof |
| ES2923942T3 (es) | 2013-11-06 | 2022-10-03 | Us Health | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| WO2016085990A1 (en) * | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
| US10733023B1 (en) * | 2015-08-06 | 2020-08-04 | D2Iq, Inc. | Oversubscription scheduling |
| WO2017156362A1 (en) | 2016-03-11 | 2017-09-14 | President And Fellows Of Harvard College | Modulating t cell survival by targeting the one-carbon metabolic pathway |
| IL263540B2 (en) * | 2016-06-07 | 2023-07-01 | Novabiotics Ltd | Microparticles that include a sulfur-containing compound |
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| SG10201609048RA (en) * | 2016-10-28 | 2018-05-30 | Agency Science Tech & Res | Antisense oligonucleotides |
| WO2018093364A1 (en) * | 2016-11-16 | 2018-05-24 | The Regents Of The University Of California | Formulations of cysteamine and cystamine |
| US11579147B2 (en) | 2017-09-25 | 2023-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of VNN1 as a biomarker and a therapeutic target in sarcomas |
| WO2019070478A1 (en) * | 2017-10-06 | 2019-04-11 | Rush University Medical Center | USE OF A BENZOATE-CONTAINING COMPOSITION FOR TREATING GLYCINIC ENCEPHALOPATHY |
| WO2020210207A2 (en) | 2019-04-11 | 2020-10-15 | Northeastern University | Oligonucleotide-polymer miktoarm conjugates and methods of use |
| US11162102B2 (en) | 2019-05-13 | 2021-11-02 | Dna Twopointo Inc. | Modifications of mammalian cells using artificial micro-RNA to alter their properties and the compositions of their products |
| CN115590945B (zh) * | 2022-08-19 | 2023-06-06 | 北京市肿瘤防治研究所 | 一种用于治疗肿瘤的多肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4748100A (en) | 1999-04-29 | 2000-11-17 | Merck Patent Gmbh | Glycine cleavage system inhibitors as potential antipsychotics |
| WO2004024129A1 (en) | 2002-09-10 | 2004-03-25 | Samir Chachoua | Induced remission therapy |
| WO2008133292A1 (ja) | 2007-04-25 | 2008-11-06 | Japan Health Sciences Foundation | スキルス型がんの疾患関連たんぱく質 |
| WO2011031308A1 (en) | 2009-09-09 | 2011-03-17 | Cytokinetics, Incorporated | Novel combinations |
| CN101797242A (zh) * | 2010-04-07 | 2010-08-11 | 中国科学技术大学 | 半胱胺在制备治疗癌症的药物中的应用 |
-
2013
- 2013-02-11 US US14/377,470 patent/US9493775B2/en active Active
- 2013-02-11 EP EP13746071.3A patent/EP2811991A4/en not_active Withdrawn
- 2013-02-11 CA CA2864161A patent/CA2864161A1/en not_active Abandoned
- 2013-02-11 AU AU2013216703A patent/AU2013216703A1/en not_active Abandoned
- 2013-02-11 JP JP2014556787A patent/JP2015509489A/ja active Pending
- 2013-02-11 NZ NZ630026A patent/NZ630026A/en not_active IP Right Cessation
- 2013-02-11 SG SG11201404779TA patent/SG11201404779TA/en unknown
- 2013-02-11 WO PCT/US2013/025601 patent/WO2013120086A1/en not_active Ceased
-
2014
- 2014-08-10 IL IL234046A patent/IL234046A0/en unknown
- 2014-08-20 ZA ZA2014/06124A patent/ZA201406124B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509489A5 (enExample) | ||
| Trotta et al. | Mitochondrial dynamics as regulators of cancer biology | |
| Greuber et al. | Role of ABL family kinases in cancer: from leukaemia to solid tumours | |
| Yu et al. | Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial–mesenchymal transition | |
| Barboro et al. | Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression | |
| Cipriano et al. | FAM83B mediates EGFR-and RAS-driven oncogenic transformation | |
| Maniswami et al. | PLK4: a link between centriole biogenesis and cancer | |
| Sun et al. | Alpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway | |
| Wandzioch et al. | PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells | |
| Trigka et al. | A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features | |
| Van der Linden et al. | MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL | |
| Wu et al. | LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway. | |
| Perez-Lorenzo et al. | A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms | |
| Lothong et al. | Collagen XVII inhibits breast cancer cell proliferation and growth through deactivation of the AKT/mTOR signaling pathway | |
| Zhao et al. | Role of EZH2 in oral squamous cell carcinoma carcinogenesis | |
| Zhang et al. | Overexpression of HOTTIP promotes proliferation and drug resistance of lung adenocarcinoma by regulating AKT signaling pathway. | |
| US20220073998A1 (en) | Methods and Compositions For Identifying And Treating Patients With Small Cell Lung Cancer | |
| Li et al. | The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer | |
| TWI567391B (zh) | 辨識早期肺腺癌病患之次群組之生物標記 | |
| Yang et al. | Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma | |
| Shrestha et al. | Hakai, an E3-ligase for E-cadherin, stabilizes δ-catenin through Src kinase | |
| Guda et al. | The expression and activation of extracellular signal-regulated kinase-1/2 and proliferating cell nuclear antigen content in normal tissue and human thyroid tumors | |
| You et al. | Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma | |
| Lim et al. | Direct regulation of TLR5 expression by caveolin-1 | |
| Hu et al. | Inhibition of Apoc1 reverses resistance of sorafenib by promoting ferroptosis in esophageal cancers |